Article

Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies

2022-01-31

Abstract excerpt

SARS-CoV-2 has caused immeasurable damage worldwide and available treatments with high efficacy are still scarce. With the continuous emergence of new variants of the virus, such as Omicron, Alpha, Beta, Gamma, and Delta - the so-called variants of concern, the available therapeutic and prevention strategies had to return to the experimental trial to verify their effectiveness against them. This work aims to expan...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 280057f5-cf38-5062-a565-2fea81f4ec90
DOI: 10.1101/2022.01.29.478316

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodiesDOI 10.1101/2022.01.29.478316Read

Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies.Semantic proximity Read

SARS-COV-2 Omicron variant predicted to exhibit higher affinity to ACE-2 receptor and lower affinity to a large range of neutralizing antibodies, using a rapid computational platformSemantic proximity Read

A novel consensus-based computational pipeline for rapid screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including omicron variantSemantic proximity Read

A novel consensus‐based computational pipeline for screening of antibody therapeutics for efficacy against SARS‐CoV‐2 variants of concern including Omicron variantSemantic proximity Read

Structural and computational insights into the SARS-CoV-2 Omicron RBD-ACE2 interactionSemantic proximity Read

Identification of key mutations responsible for the enhancement of receptor-binding affinity and immune escape of SARS-CoV-2 Omicron variant.Semantic proximity Read

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.Semantic proximity Read

Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants.Semantic proximity Read

Binding ability of Delta and Omicron towards the angiotensin-converting enzyme 2 receptor and antibodies: a computational study.Semantic proximity Read

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studiesSemantic proximity Read

Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic AntibodiesSemantic proximity Read

Predicting Antibody and ACE2 Affinity for SARS-CoV-2 BA.2.86 and JN.1 with <i>In Silico</i> Protein Modeling and DockingSemantic proximity Read